Integrating Risk-Based Care for Patients With Chronic Kidney Disease in the Community: Study Protocol for a Cluster Randomized Trial

Oksana Harasemiw, Neil Drummond, Alexander Singer, Aminu Bello, Paul Komenda, Claudio Rigatto, Jordyn Lerner, Dwight Sparkes, Thomas W Ferguson, Navdeep Tangri, Oksana Harasemiw, Neil Drummond, Alexander Singer, Aminu Bello, Paul Komenda, Claudio Rigatto, Jordyn Lerner, Dwight Sparkes, Thomas W Ferguson, Navdeep Tangri

Abstract

Background: A risk-based model of care for managing patients with chronic kidney disease (CKD) using the Kidney Failure Risk Equation (KFRE) has been successfully integrated into nephrology care pathways in several jurisdictions. However, as most patients with CKD can be managed in primary care, the next pertinent steps would be to integrate the KFRE into primary care pathways.

Objective: Using a risk-based approach for guiding CKD care in the primary care setting, the objective of the study is to develop, implement, and evaluate tools that can be used by patients and providers.

Design: This study is a multicenter cluster randomized control trial.

Setting: Thirty-two primary care clinics belonging to the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) across Manitoba and Alberta.

Patients: All patients at least 18 years old or older with CKD categories G3-G5 attending the participating clinics; we estimate each clinic will have an average of 185 patients with CKD.

Methods: Thirty-two primary care clinics will be randomized to receive either an active knowledge translation intervention or no intervention. The intervention involves the addition of the KFRE and decision aids to clinics' Data Presentation Tool (DPT), as well as patient-facing visual aids, a medical detailing visit, and sentinel feedback reports. Control clinics will only be exposed to current guidelines for CKD management, without active dissemination.

Measurements: Data from the CPCSSN repository will be used to assess whether a risk-based care approach affected management of CKD. Primary outcomes are as follows: the proportion of patients with measured urine albumin-to-creatinine ratio, and the proportion of patients being appropriately treated with angiotensin-converting enzyme inhibitor or angiotensin receptor blockers. Secondary outcomes are as follows: the optimal management of diabetes (hemoglobin A1C <8.5%, and the use of sodium-glucose cotransporter-2 inhibitors in CKD G3 patients), hypertension (office blood pressure <130/80 for patients with diabetes, 140/90 for those without), and cardiovascular risk (statin prescription); prescriptions of nonsteroidal anti-inflammatory drugs; and decline in estimated glomerular filtration rate (eGFR). In addition, in a substudy, we will measure CKD-specific health literacy and trust in physician care via surveys administered in the clinic post-visit. At the provider level, we will measure satisfaction with the risk prediction tools. Lastly, at the health system level, outcomes include cost of CKD care, and appropriate referrals for patients at high risk of kidney failure based on provincial guidelines. Primary and secondary outcomes will be measured at the patient level and enumerated at the clinic level 1 year after the intervention implementation, except for decline in eGFR, which will be measured 2 years postintervention.

Limitations: Limitations include scalability of the proposal in other health care systems.

Conclusions: If successful, this intervention has the potential to improve the management of patients with CKD within Canadian primary care settings, leading to health and economic benefits, and influencing practice guidelines.

Trial registration: ClinicalTrials.gov identifier: NCT03365063.

Keywords: chronic kidney disease; cluster randomized trial; kidney failure risk; knowledge translation; patient-oriented research; randomized controlled trial.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Study intervention and timeline. Note. AB = Alberta; MB = Manitoba; CKD = chronic kidney disease; KFRE = Kidney Failure Risk Equation; KT = knowledge translation; CPCSSN = Canadian Primary Care Sentinel Surveillance Network; DPT = Data Presentation Tool; eGFR = estimated glomerular filtration rate.

References

    1. Tahir MA, Dmitrieva O, deLusignan S, et al. Confidence and quality in managing CKD compared with other cardiovascular diseases and diabetes mellitus: a linked study of questionnaire and routine primary care data. BMC Fam Pract. 2011;12:83-89.
    1. Plantinga LC, Tuot DS, Powe NR. Awareness of chronic kidney disease among patients and providers. Adv Chronic Kidney Dis. 2010;17(3):225-236.
    1. Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Chronic kidney disease in primary care: outcomes after five years in a prospective cohort study. PLoS Med. 2016;13(9):e1002128.
    1. Zhang Q, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8(117):1-13.
    1. Canadian Institute for Health Information. Annual statistics on organ replacement in Canada: dialysis, transplantation and donation, 2006 to 2015; February 2017. . Accessed March 20, 2019.
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
    1. Manns BJ, Mendelssohn D, Taub K. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ. 2007;7(2-3):149-169.
    1. Komenda P, Copland M, Makwana J, Djurdjev O, Sood MM, Levin A. The cost of starting and maintaining a large home hemodialysis program. Kidney Int. 2010;77(11):1039-1045.
    1. Manns B, Tonelli M, Culleton B, et al. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. Clin J Am Soc Nephrol. 2012;7(4):565-572.
    1. Bello AK, Ronksley PE, Tangri N, et al. Prevalence and demographics of CKD in Canadian primary care practices: a cross-sectional study. Kidney Int Reports. 2019;4(4):561-570
    1. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
    1. Appel LJ, Middleton J, Miller E, et al. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003;14(7, suppl 2):S166-S172.
    1. Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011;123(10):1098-1107.
    1. Grill S, Brimble A. Approach to the detection and management of chronic kidney disease: what primary care providers need to know. Canadian Family Physician|Le Médecin de famille canadien. 2018;64:728-735.
    1. Strippoli GFM, Bonifati C, Craig M, SD Navaneethan, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;(4):CD006257.
    1. O’Hare AM, Bertenthal D, Walter LC, et al. When to refer patients with chronic kidney disease for vascular access surgery: should age be a consideration. Kidney Int. 2007;71(6):555-561.
    1. O’Hare AM, Batten A, Burrows NR, et al. Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis. Am J Kidney Dis. 2012;59(4):513-522.
    1. Tangri N, Stevens L, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559.
    1. Tangri N, Kitsios GD, Inker LA, et al. Risk prediction models for patients with chronic kidney disease: a systematic review. Ann Intern Med. 2013;158(8):596-603.
    1. Inston N, Lok CE. Improving precision in prediction: using kidney failure risk equations as a potential adjunct to vascular access planning. J Vasc Access. 2018;20(1):95-97.
    1. Weijer C, Grimshaw JM, Eccles MP, et al. The Ottawa statement on the ethical design and conduct of cluster randomized trials. PLoS Med. 2012;9(11):e1001346-e1100139.
    1. Williamson T, Green ME, Birtwhistle R, et al. Validating the 8 CPCSSN case definitions for chronic disease surveillance in a primary care database of electronic health records. Ann Fam Med. 2014;12(4):367-372.
    1. Birtwhistle R. Canadian Primary Care Sentinel Surveillance Network: a developing resource for family medicine and public health. Can Fam Physician. 2011;57(10):1219-1220.
    1. Queenan JA, Williamson T, Khan S, et al. Representativeness of patients and providers in the Canadian Primary Care Sentinel Surveillance Network: a cross-sectional study. CMAJ Open. 2016;4(1):E28-E32.
    1. Birtwhistle R, Queenan JA. Update from CPCSSN. Can Fam Physician|Le Médecin Fam Can. 2016;62:851.
    1. Greiver M, Drummond N, Birtwhistle R, Queenan J, Lambert-Lanning A, Jackson D. Using EMRs to fuel quality improvement. Can Fam Physician. 2015;61(1):92, e68-e69.
    1. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2012;(6):1-227. . Accessed March 20, 2019.
    1. Wright JA, Wallston KA, Elasy TA, Ikizler TA, Cavanaugh KL. Development and results of a kidney disease knowledge survey given to patients with CKD. Am J Kidney Dis. 2011;57(3):387-395.
    1. Thom DH, Ribisl KM, Stewart AL, Luke DA. Further validation and reliability testing of the Trust in Physician Scale. Med Care. 1999;37(5):510-517.
    1. Littenberg B, MacLean CD. Intra-cluster correlation coefficients in adults with diabetes in primary care practices: the Vermont Diabetes Information System field survey. BMC Med Res Methodol. 2006;6:20.
    1. Fox CH, Brooks A, Zayas LE, McClellan W, Murray B. Primary care physicians’ knowledge and practice patterns in the treatment of chronic kidney disease: an Upstate New York Practice-based Research Network (UNYNET) Study. J Am Board Fam Med. 2006;19(1):54-61.
    1. Hingwala J, Bhangoo S, Hiebert B, et al. Evaluating the implementation strategy for estimated glomerular filtration rate reporting in Manitoba: the effect on referral numbers, wait times, and appropriateness of consults. Can J Kidney Health Dis. 2014;1:9-8.
    1. Légaré F, Witteman HO. Shared decision making: examining key elements and barriers to adoption into routine clinical practice. Health Aff. 2013;32(2):276-284.
    1. Cavanaugh KL, Wingard RL, Hakim RM, et al. Low health literacy associates with increased mortality in ESRD. J Am Soc Nephrol. 2010;21(11):1979-1985.
    1. Dageforde LA, Cavanaugh KL. Health literacy: emerging evidence and applications in kidney disease care. Adv Chronic Kidney Dis. 2013;20(4):311-319.
    1. Osborn CY, Cavanaugh K, Wallston KA, et al. Health literacy explains racial disparities in diabetes medication adherence. J Health Commun. 2011;16(suppl 3):268-278.
    1. Levin A, Adams E, Barrett BJ, et al. Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): form and Function. Can J Kidney Health Dis. 2018;5:1-12. doi:10.1177/2054358117749530.

Source: PubMed

3
Prenumerera